Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line

J. W. Smit; J. P. Shröder-van der Elst; M. Karperien; I. Que; G. van der Pluijm; B. Goslings; J. A. Romijn; D. van der Heide

doi:10.1089/thy.2000.10.939

Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line

J. W. Smit
, J. P. Shröder-van der Elst
, M. Karperien
, I. Que
, G. van der Pluijm
, B. Goslings
, J. A. Romijn
, D. van der Heide

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Uptake of iodide is a prerequisite for radioiodine therapy in thyroid cancer. However, loss of iodide uptake is frequently observed in metastasized thyroid cancer, which may be explained by diminished expression of the human sodium iodide symporter (hNIS). Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer. In this study, we report the stable transfection of a hNIS expression vector into the hNIS defective follicular thyroid carcinoma cell line FTC133. Stablely transfected colonies exhibited high uptake of Na125I, which could be blocked completely with sodiumperchlorate. hNIS mRNA expression corresponded with iodide uptake in semiquantitative polymerase chain reaction. Iodide uptake was maximal after 60 minutes, whereas iodide efflux was complete after 120 minutes. hNIS transfected FTC133 and control cell lines injected subcutaneously in nude mice formed tumors after 6 weeks. Iodide uptake in the hNIS transfected tumor was much higher than in the nontransfected tumor, which corresponded with hNIS mRNA expression in tumors

Original language	English
Pages (from-to)	939-943
Journal	Thyroid
Volume	10
Issue number	11
DOIs	https://doi.org/10.1089/thy.2000.10.939
Publication status	Published - 2000

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1089/thy.2000.10.939

Cite this

Smit, J. W., Shröder-van der Elst, J. P., Karperien, M., Que, I., van der Pluijm, G., Goslings, B., Romijn, J. A., & van der Heide, D. (2000). Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid, 10(11), 939-943. https://doi.org/10.1089/thy.2000.10.939

@article{6759ce6b84364b208db90df57aa32414,

title = "Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line",

abstract = "Uptake of iodide is a prerequisite for radioiodine therapy in thyroid cancer. However, loss of iodide uptake is frequently observed in metastasized thyroid cancer, which may be explained by diminished expression of the human sodium iodide symporter (hNIS). Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer. In this study, we report the stable transfection of a hNIS expression vector into the hNIS defective follicular thyroid carcinoma cell line FTC133. Stablely transfected colonies exhibited high uptake of Na125I, which could be blocked completely with sodiumperchlorate. hNIS mRNA expression corresponded with iodide uptake in semiquantitative polymerase chain reaction. Iodide uptake was maximal after 60 minutes, whereas iodide efflux was complete after 120 minutes. hNIS transfected FTC133 and control cell lines injected subcutaneously in nude mice formed tumors after 6 weeks. Iodide uptake in the hNIS transfected tumor was much higher than in the nontransfected tumor, which corresponded with hNIS mRNA expression in tumors",

author = "Smit, \{J. W.\} and \{Shr{\"o}der-van der Elst\}, \{J. P.\} and M. Karperien and I. Que and \{van der Pluijm\}, G. and B. Goslings and Romijn, \{J. A.\} and \{van der Heide\}, D.",

year = "2000",

doi = "10.1089/thy.2000.10.939",

language = "English",

volume = "10",

pages = "939--943",

journal = "Thyroid",

issn = "1050-7256",

publisher = "Mary Ann Liebert Inc.",

number = "11",

}

Smit, JW, Shröder-van der Elst, JP, Karperien, M, Que, I, van der Pluijm, G, Goslings, B, Romijn, JA & van der Heide, D 2000, 'Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line', Thyroid, vol. 10, no. 11, pp. 939-943. https://doi.org/10.1089/thy.2000.10.939

TY - JOUR

T1 - Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line

AU - Smit, J. W.

AU - Shröder-van der Elst, J. P.

AU - Karperien, M.

AU - Que, I.

AU - van der Pluijm, G.

AU - Goslings, B.

AU - Romijn, J. A.

AU - van der Heide, D.

PY - 2000

Y1 - 2000

N2 - Uptake of iodide is a prerequisite for radioiodine therapy in thyroid cancer. However, loss of iodide uptake is frequently observed in metastasized thyroid cancer, which may be explained by diminished expression of the human sodium iodide symporter (hNIS). Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer. In this study, we report the stable transfection of a hNIS expression vector into the hNIS defective follicular thyroid carcinoma cell line FTC133. Stablely transfected colonies exhibited high uptake of Na125I, which could be blocked completely with sodiumperchlorate. hNIS mRNA expression corresponded with iodide uptake in semiquantitative polymerase chain reaction. Iodide uptake was maximal after 60 minutes, whereas iodide efflux was complete after 120 minutes. hNIS transfected FTC133 and control cell lines injected subcutaneously in nude mice formed tumors after 6 weeks. Iodide uptake in the hNIS transfected tumor was much higher than in the nontransfected tumor, which corresponded with hNIS mRNA expression in tumors

AB - Uptake of iodide is a prerequisite for radioiodine therapy in thyroid cancer. However, loss of iodide uptake is frequently observed in metastasized thyroid cancer, which may be explained by diminished expression of the human sodium iodide symporter (hNIS). Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer. In this study, we report the stable transfection of a hNIS expression vector into the hNIS defective follicular thyroid carcinoma cell line FTC133. Stablely transfected colonies exhibited high uptake of Na125I, which could be blocked completely with sodiumperchlorate. hNIS mRNA expression corresponded with iodide uptake in semiquantitative polymerase chain reaction. Iodide uptake was maximal after 60 minutes, whereas iodide efflux was complete after 120 minutes. hNIS transfected FTC133 and control cell lines injected subcutaneously in nude mice formed tumors after 6 weeks. Iodide uptake in the hNIS transfected tumor was much higher than in the nontransfected tumor, which corresponded with hNIS mRNA expression in tumors

U2 - 10.1089/thy.2000.10.939

DO - 10.1089/thy.2000.10.939

M3 - Article

C2 - 11128720

SN - 1050-7256

VL - 10

SP - 939

EP - 943

JO - Thyroid

JF - Thyroid

IS - 11

ER -

Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this